P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer

Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01267357

Enrollment

Registered

2010-12-28

Start date

2010-07-31

Completion date

Unknown

Last updated

2010-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Serous Papillary Endometrial Cancer

Keywords

Serous Papillary Endometrial Cancer, Endometrioid endometrial cancer, biomarkers, P16, P53, Prognosis

Brief summary

P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value. The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker. following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins. Blocks from endometrioid endometrial cancer will be used as a control group.

Interventions

OTHERno intervention

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diagnosis of endometrial cancer * histology block exists in hospital's library

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame
Overall survival	last followup (2-10 years)

Secondary

Measure	Time frame
progression free survival	Current follow up (2-10 years)
correlation of P16 stain with histological diagnosis	at last follow up (2-10 years)

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026